线粒体功能障碍在急性肾损伤向慢性肾脏疾病转变中的作用

基础医学与临床 ›› 2021, Vol. 41 ›› Issue (4): 589-592.

线粒体功能障碍在急性肾损伤向慢性肾脏疾病转变中的作用

张欣, 廖晓辉^*

重庆医科大学附属第二医院肾内科, 重庆 400010

收稿日期:2020-08-28 修回日期:2020-12-20 出版日期:2021-04-05 发布日期:2021-04-05
通讯作者: ^*lxh@hospital.cqmu.edu.cn
基金资助:
国家自然科学基金(81873604)

Role of mitochondrial dysfunction in the transition of acute renal injury to chronic kidney disease

ZHANG Xin, LIAO Xiao-hui^*

Department of Nephrology, the Second Affiliated Hospital of Chongqing Medical University, Chongqing 400010, China

Received:2020-08-28 Revised:2020-12-20 Online:2021-04-05 Published:2021-04-05
Contact: ^*lxh@hospital.cqmu.edu.cn

摘要/Abstract

摘要： 急性肾损伤(AKI)是一种发病率较高的临床综合征,会使远期慢性肾脏病(CKD)的发病率明显上升,其机制目前尚不完全明确,可能包括细胞周期停滞、小管上皮周围毛细血管变少、炎性细胞浸润等。线粒体功能障碍在其中的作用主要包括导致了过度氧化应激、促进炎性反应的发生及进展、直接诱导肾小管细胞凋亡等。

关键词: 急性肾损伤, 慢性肾脏病, 线粒体, 氧化应激反应

Abstract: Acute kidney injury (AKI) is a clinical syndrome with a high incidence, which will significantly increase the incidence of chronic kidney disease (CKD). The mechanism of AKI-CKD transition is not clear. It may include cell cycle arrest, fewer capillaries around the tubule epithelium, inflammatory cell infiltration and so on. Mitochondrial dysfunction consequently leads to oxidative stress, inflammation response and renal tubular cell apoptosis resulting in AKI-CKD transition conclusively.

Key words: acute kidney injury, chronic kidney disease, mitochondrion, oxidative stress

中图分类号:

张欣, 廖晓辉. 线粒体功能障碍在急性肾损伤向慢性肾脏疾病转变中的作用[J]. 基础医学与临床, 2021, 41(4): 589-592.

ZHANG Xin, LIAO Xiao-hui. Role of mitochondrial dysfunction in the transition of acute renal injury to chronic kidney disease[J]. Basic & Clinical Medicine, 2021, 41(4): 589-592.

参考文献

[1] Fiorentino M, Grandaliano G, Gesualdo L, et al. Acute kidney injury to chronic kidney disease transition[J]. Contrib Nephrol, 2018, 193: 45-54.
[2] Hoste EaJ, Kellum JA, Selby NM, et al. Global epidemiology and outcomes of acute kidney injury[J]. Nat Rev Nephrol, 2018, 14: 607-625.
[3] Santos RPD, Carvalho ARS, Peres LaB, et al. An epidemiologic overview of acute kidney injury in intensive care units[J]. Rev Assoc Med Bras (1992), 2019, 65: 1094-1101.
[4] Coca SG, Singanamala S, Parikh CR. Chronic kidney disease after acute kidney injury: a systematic review and meta-analysis[J]. Kidney Int, 2012, 81: 442-448.
[5] Selby NM, Taal MW. Long-term outcomes after AKI-a major unmet clinical need[J]. Kidney Int, 2019, 95: 21-23.
[6] Venkatachalam MA, Weinberg JM, Kriz W, et al. Failed tubule recovery, AKI-CKD transition, and kidney disease progression[J]. J Am Soc Nephrol, 2015, 26: 1765-1776.
[7] Shu S, Zhu J, Liu Z, et al. Endoplasmic reticulum stress is activated in post-ischemic kidneys to promote chronic kidney disease[J]. E Bio Medicine, 2018, 37: 269-280.
[8] Guzzi F, Cirillo L, Roperto RM, et al. Molecular mechanisms of the acute kidney injury to chronic kidney disease transition: an updated view[J]. Int J Mol Sci, 2019, 20.doi:10.3390/ijms20194941.
[9] Franzin R, Stasi A, Fiorentino M, et al. Inflammaging and complement system: a link between acute kidney injury and chronic graft damage[J]. Front Immunol, 2020, 11.doi:10.3389/fimmu.2020.00734.
[10] Black LM, Lever JM, Traylor AM, et al. Divergent effects of AKI to CKD models on inflammation and fibrosis[J]. Am J Physiol Renal Physiol, 2018, 315: F1107-F1118.
[11] Chou YH, Huang TM, Pan SY, et al. Renin-angiotensin system inhibitor is associated with lower risk of ensuing chronic kidney disease after functional recovery from acute kidney injury[J]. Sci Rep, 2017, 7.doi:10.1038/srep46518.
[12] Su H, Ye C, Lei CT, et al. Subcellular trafficking of tubular MDM2 implicates in acute kidney injury to chronic kidney disease transition during multiple low-dose cisplatin exposure[J]. FASEB J, 2020, 34: 1620-1636.
[13] Szeto HH, Liu S, Soong Y, et al. Mitochondria protection after acute ischemia prevents prolonged upregulation of IL-1beta and IL-18 and arrests CKD[J]. J Am Soc Nephrol, 2017, 28: 1437-1449.
[14] Bataille A, Galichon P, Chelghoum N, et al. Increased fatty acid oxidation in differentiated proximal tubular cells surviving a reversible episode of acute kidney injury[J]. Cell Physiol Biochem, 2018, 47: 1338-1351.
[15] Chen DQ, Feng YL, Chen L, et al. Poricoic acid A enhances melatonin inhibition of AKI-to-CKD transition by regulating Gas6/AxlNFkappaB/Nrf2 axis[J]. Free Radic Biol Med, 2019, 134: 484-497.
[16] Skrypnyk NI, Voziyan P, Yang H, et al. Pyridoxamine reduces postinjury fibrosis and improves functional recovery after acute kidney injury[J]. Am J Physiol Renal Physiol, 2016, 311: F268-277.
[17] Liu Q, Zhang D, Hu D, et al. The role of mitochondria in NLRP3 inflammasome activation[J]. Mol Immunol, 2018, 103: 115-124.
[18] Maekawa H, Inagi R. Pathophysiological role of organelle stress/crosstalk in AKI-to-CKD Transition[J]. Semin Nephrol, 2019, 39: 581-588.
[19] Yang H, Li R, Zhang L, et al. p53-cyclophilin D mediates renal tubular cell apoptosis in ischemia-reperfusion-induced acute kidney injury[J]. Am J Physiol Renal Physiol, 2019, 317: F1311-F1317.
[20] Zhao JY, Wang XL, Yang YC, et al. Upregulated miR-101 inhibits acute kidney injury-chronic kidney disease transition by regulating epithelial-mesenchymal transition[J]. Hum Exp Toxicol, 2020.doi:10.1177/0960327120937334.
[21] Zhao L, Han F, Wang J, et al. Current understanding of the administration of mesenchymal stem cells in acute kidney injury to chronic kidney disease transition: a review with a focus on preclinical models[J]. Stem Cell Res Ther, 2019, 10.doi:10.1186/s13287-019-1507-3.
[22] Gao L, Zhong X, Jin J, et al. Potential targeted therapy and diagnosis based on novel insight into growth factors, receptors, and downstream effectors in acute kidney injury and acute kidney injury-chronic kidney disease progression[J]. Signal Transduct Target Ther, 2020, 5.doi:10.1038/s41392-020-0106-1.
[23] Aparicio-Trejo OE, Avila-Rojas SH, Tapia E, et al. Chronic impairment of mitochondrial bioenergetics and beta-oxidation promotes experimental AKI-to-CKD transi-tion induced by folic acid[J]. Free Radic Biol Med, 2020, 154: 18-32.
[24] Zhang W, Sha Y, Wei K, et al. Rotenone ameliorates chronic renal injury caused by acute ischemia/reperfusion[J]. Oncotarget, 2018, 9: 24199-24208.